These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 15120940

  • 1. Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.
    Kawano T, Horiguchi-Yamada J, Saito S, Iwase S, Furukawa Y, Kano Y, Yamada H.
    Leuk Res; 2004 Jun; 28(6):623-9. PubMed ID: 15120940
    [Abstract] [Full Text] [Related]

  • 2. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.
    Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M.
    J Cell Physiol; 2004 Mar; 198(3):370-6. PubMed ID: 14755542
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 4. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T, Horiguchi-Yamada J, Iwase S, Furukawa Y, Kano Y, Yamada H.
    Mol Cell Biochem; 2004 Mar 01; 258(1-2):25-33. PubMed ID: 15030167
    [Abstract] [Full Text] [Related]

  • 5. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM, Liu JC.
    J Cell Physiol; 2009 Mar 01; 218(3):568-74. PubMed ID: 19006173
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 10. Role of ERK activation in growth and erythroid differentiation of K562 cells.
    Woessmann W, Mivechi NF.
    Exp Cell Res; 2001 Apr 01; 264(2):193-200. PubMed ID: 11262176
    [Abstract] [Full Text] [Related]

  • 11. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
    Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S.
    Cancer Res; 1989 Jan 15; 49(2):331-4. PubMed ID: 2910452
    [Abstract] [Full Text] [Related]

  • 12. ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5'-triphosphate-mediated terminal erythroid differentiation of K562 cells.
    Moosavi MA, Yazdanparast R, Lotfi A.
    Int J Biochem Cell Biol; 2007 Jan 15; 39(9):1685-97. PubMed ID: 17543571
    [Abstract] [Full Text] [Related]

  • 13. ERK/MAPK pathway is required for changes of cyclin D1 and B1 during phorbol 12-myristate 13-acetate-induced differentiation of K562 cells.
    Lee CH, Yun HJ, Kang HS, Kim HD.
    IUBMB Life; 1999 Dec 15; 48(6):585-91. PubMed ID: 10683762
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 15; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 16. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
    Brózik A, Casey NP, Hegedus C, Bors A, Kozma A, Andrikovics H, Geiszt M, Német K, Magócsi M.
    Ann N Y Acad Sci; 2006 Dec 31; 1090():344-54. PubMed ID: 17384279
    [Abstract] [Full Text] [Related]

  • 17. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P.
    Leuk Res; 2008 Jun 31; 32(6):855-64. PubMed ID: 18083230
    [Abstract] [Full Text] [Related]

  • 18. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
    Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y, Kizaki M.
    Leuk Lymphoma; 2003 Nov 31; 44(11):1987-96. PubMed ID: 14738154
    [Abstract] [Full Text] [Related]

  • 19. Activin A induces erythroid gene expressions and inhibits mitogenic cytokine-mediated K562 colony formation by activating p38 MAPK.
    Huang HM, Chiou HY, Chang JL.
    J Cell Biochem; 2006 Jul 01; 98(4):789-97. PubMed ID: 16440334
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.